journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://read.qxmd.com/read/31054778/somatic-mutation-of-lrp1b-is-associated-with-tumor-mutational-burden-in-patients-with-lung-cancer
#1
LETTER
Shaowei Lan, Hui Li, Ying Liu, Lixia Ma, Xianhong Liu, Yan Liu, Shi Yan, Ying Cheng
No abstract text is available yet for this article.
April 28, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31031052/corrigendum-to-adjuvant-chemotherapy-following-stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer-is-associated-with-lower-overall-survival-a-national-cancer-database-analysis-lung-cancer-volume-130-april-2019-162-168
#2
Corey C Foster, Chad G Rusthoven, David J Sher, Lawrence Feldman, Mary Pasquinelli, Michael T Spiotto, Matthew Koshy
No abstract text is available yet for this article.
April 25, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31029398/corrigendum-to-analysis-of-central-nervous-system-efficacy-in-the-j-alex-study-of-alectinib-versus-crizotinib-in-alk-positive-non-small-cell-lung-cancer-lung-cancer-121-july-2018-pages-37-40
#3
Makoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Tomohiro Tanaka, Hiroshi Kuriki, Ali Zeaiter, Tomohide Tamura
No abstract text is available yet for this article.
April 24, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31031051/correspondence-regarding-low-dose-computed-tomography-screening-for-lung-cancer-in-people-with-workplace-exposure-to-asbestos
#4
LETTER
Edward J A Harris, A W Musk, Nicholas DeKlerk, Fraser J H Brims
No abstract text is available yet for this article.
April 20, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31014853/corrigendum-to-necitumumab-plus-gemcitabine-and-cisplatin-versus-gemcitabine-and-cisplatin-alone-as-first-line-treatment-for-stage-iv-squamous-non-small-cell-lung-cancer-a-phase-1b-and-randomized-open-label-multicenter-phase-2-trial-in-japan-lung-cancer-129
#5
Satoshi Watanabe, Hiroshige Yoshioka, Hiroshi Sakai, Katsuyuki Hotta, Mitsuhiro Takenoyama, Kazuhiko Yamada, Shunichi Sugawara, Yuichi Takiguchi, Yukio Hosomi, Keisuke Tomii, Seiji Niho, Nobuyuki Yamamoto, Makoto Nishio, Yuichiro Ohe, Terufumi Kato, Toshiaki Takahashi, Ami Kamada, Kazumi Suzukawa, Yukie Omori, Sotaro Enatsu, Kazuhiko Nakagawa, Tomohide Tamura
No abstract text is available yet for this article.
April 20, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31036377/tuberous-sclerosis-complex-a-rare-etiology-of-multiple-subsolid-nodules
#6
LETTER
Lea Lantuéjoul, Guillaume Pontarollo, Emilie Reymond, Marie Brevet, Françoise Thivolet-Béjui, Gilbert R Ferretti
No abstract text is available yet for this article.
April 16, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30935718/response-to-comment-on-synchronous-multiple-non-small-cell-lung-cancers-in-an-allograft-lung-recipient
#7
LETTER
Jean-Louis Pujol, Sébastien Bommart, Pascal Pujol
No abstract text is available yet for this article.
March 26, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30890378/response-to-comment-on-correlation-of-tumor-spread-through-air-spaces-and-clinicopathological-characteristics-in-surgically-resected-lung-adenocarcinomas
#8
LETTER
Min-Shu Hsieh, Mong-Wei Lin
No abstract text is available yet for this article.
March 13, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30878212/corrigendum-to-correlation-of-tumor-spread-through-air-spaces-and-clinicopathological-characteristics-in-surgically-resected-lung-adenocarcinomas-lung-cancer-126-2018-189-193
#9
Szu-Yen Hu, Min-Shu Hsieh, Hsao-Hsun Hsu, Tung-Ming Tsai, Xu-Heng Chiang, Kuan-Chuan Tsou, Hsien-Chi Liao, Mong-Wei Lin, Jin-Shing Chen
No abstract text is available yet for this article.
March 13, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30876688/corrigendum-to-genetic-alterations-of-driver-genes-as-independent-prognostic-factors-for-disease-free-survival-in-patients-with-resected-non-small-cell-lung-cancer-lung-cancer-128-2019-152-157
#10
Akira Ono, Mitsuhiro Isaka, Masakuni Serizawa, Katsuhiro Omae, Hideaki Kojima, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Kenichi Urakami, Takeshi Nagashima, Takashi Sugino, Masatoshi Kusuhara, Toshiaki Takahashi, Ken Yamaguchi, Yasuhisa Ohde
No abstract text is available yet for this article.
March 12, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/30879776/what-impacts-the-cost-effectiveness-of-pd-l1-testing-in-non-small-cell-lung-cancer
#11
LETTER
Sara Bravaccini
Programmed Death Ligand 1(PD-L1) testing is recommended for patients with NonSmall Cell Lung Cancer (NSCLC) at stage IIIB and IV, adenocarcinoma and squamous cell carcinoma. Up to now, no clinical-pathological parameters are perfectly able to select a positive PD-L1-patient. For this reason PD-L1 testing is mandatory for patients with advanced NSCLC for whom an immune checkpoint inhibitor treatment is appropriate. Several studies on the cost-effectiveness of immune checkpoint inhibitors in this subset of patients have been published...
March 11, 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097102/the-novel-microrna-hsa-mir-cha1-regulates-cell-proliferation-and-apoptosis-in-human-lung-cancer-by-targeting-xiap
#12
Jung Ki Yoo, Ji Min Lee, Seung Hee Kang, Seong Ho Jeon, Chang Min Kim, Seung-Hun Oh, Chang-Hyun Kim, Nam Keun Kim, Jin Kyeoung Kim
OBJECTIVES: MicroRNAs have critical roles in cancer development by regulating the expression of oncogenes or tumor suppressor genes. We identified and characterized a novel miRNA, miR-CHA1, in human lung cancer cells. The aim of this study was to investigate its novel function in human lung cancer by targeting XIAP. MATERIAL AND METHODS: Novel miRNA cloning, Real-time qRT-PCR, western blotting, dual luciferase assay, miRNA transfection, proliferation and apoptosis assay were carried on human lung cancer cell line A549...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097101/lymphangitic-carcinomatosis-a-common-radiographic-manifestation-of-local-failure-following-extended-pleurectomy-decortication-in-patients-with-malignant-pleural-mesothelioma
#13
Ian Berger, Keith A Cengel, Charles B Simone, Evan W Alley, Leonid Roshkovan, Andrew R Haas, Akash M Patel, Urooj Khalid, Melissa J Culligan, Sally McNulty, Sunil Singhal, Joseph S Friedberg, Sharyn I Katz
INTRODUCTION: The lymphangitic carcinomatosis (LC) pattern of metastatic malignancy is associated with a poor prognosis but is currently not well defined in malignant pleural mesothelioma (MPM). Here, we report the incidence and prognostic significance of the radiographic development of LC in MPM following extended pleurectomy/decortication (EPD). METHODS: Consecutive patients with biopsy-proven MPM undergoing EPD with intraoperative photodynamic therapy (PDT) at our institution from 2008 to 2014 were included in this retrospective study...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097100/high-expression-level-of-sox2-is-significantly-associated-with-shorter-survival-in-patients-with-thymic-epithelial-tumors
#14
Guk Jin Lee, Heejung Lee, In Sook Woo, Taejung Kim, Ho Jung An, Hyun Joo Choi, Youn Soo Lee, Kyo Young Lee, Jieun Lee, Jin-Hyoung Kang
OBJECTIVES: Thymic epithelial tumors (TET) are heterogenous tumors which are composed of thymoma (TM) and thymic carcinoma (TC). We attempted to determine differences in gene expression between TM and TC, and to determine the effect of such genes on the prognosis of patients with TET. MATERIALS AND METHODS: Gene expression profiles of SOX2, OCT-4, IGF-1, IGF-1R and IR mRNA transcripts in tumor tissues of TM and TC were determined using real-time PCR (RT-PCR). We constructed tissue microarray with 140 paraffin-embedded tumor tissues and performed immunohistochemistry (IHC) for IGF-1R-related signaling molecules, including SOX2, IGF-1, IGF-1R and pAKT...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097099/demography-patterns-of-care-and-survival-outcomes-in-patients-with-malignant-tumors-of-trachea-a-systematic-review-and-individual-patient-data-analysis-of-733-patients
#15
Supriya Mallick, Rony Benson, Prashanth Giridhar, Angel Rajan Singh, Goura K Rath
BACKGROUND: Malignant tumors of the trachea (MTT) account for 0.01-0.4% of all cancer cases. The rarity of the tumor along with different histologies makes it is a great challenge on how to optimally treat tracheal tumors and most of the available data is from small retrospective data series. We performed a systematic review and individual patient data analysis to evaluate the patterns of care and survival outcomes in patient with MTT. METHODOLOGY: A comprehensive search in Pub Med and Google scholar was done to find all possible publications related to malignant tumors of the trachea...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097098/the-incidence-of-alk-inhibitor-related-pneumonitis-in-advanced-non-small-cell-lung-cancer-patients-a-systematic-review-and-meta-analysis
#16
Chong Hyun Suh, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino
INTRODUCTION: We evaluated the incidence of pneumonitis in clinical trials of anaplastic lymphoma kinase (ALK) inhibitors in patients with advanced non-small cell lung cancer (NSCLC) and compared the incidence among different cohorts, in order to identify possible predisposing factors for ALK inhibitor-related pneumonitis. METHODS: MEDLINE and EMBASE search up to 1/30/18 using the keywords, "alectinib", "ceritinib", "crizotinib", "brigatinib", and "lung cancer", resulting in a total of 20 eligible cohorts with 2261 patients treated with ALK inhibitor monotherapy for advanced NSCLC...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097097/association-between-antibiotic-immunotherapy-exposure-ratio-and-outcome-in-metastatic-non-small-cell-lung-cancer
#17
Giulia Galli, Tiziana Triulzi, Claudia Proto, Diego Signorelli, Martina Imbimbo, Marta Poggi, Giovanni Fucà, Monica Ganzinelli, Milena Vitali, Dario Palmieri, Anna Tessari, Filippo de Braud, Marina Chiara Garassino, Mario Paolo Colombo, Giuseppe Lo Russo
OBJECTIVES: Immunotherapy (IO) is effective in metastatic Non Small Cell Lung Cancer (NSCLC). Gut microbiota has an impact on immunity and its imbalance due to antibiotics may impair the efficacy of IO. We investigated this topic in a case series of NSCLC patients treated with IO. MATERIALS AND METHODS: Data about all metastatic NSCLC patients treated with IO between 04/2013 and 01/2018 were collected. Patients were stratified according to antibiotic use during the Early IO Period (EIOP), and according to the Antibiotic-Immunotherapy Exposure Ratio (AIER) defined as "days of antibiotic/days of IO" during the Whole IO Period (WIOP)...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097096/association-of-tp53-mutations-with-response-and-longer-survival-under-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer
#18
Sandra Assoun, Nathalie Theou-Anton, Marina Nguenang, Aurélie Cazes, Claire Danel, Baptiste Abbar, Johan Pluvy, Valérie Gounant, Antoine Khalil, Céline Namour, Solenn Brosseau, Gérard Zalcman
INTRODUCTION: Tumor mutational burden (TMB) correlates with response to immune checkpoint inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that TP53 mutations could reflect TMB and be associated with ICI benefit. METHODS: TP53 mutations were assessed by next-generation sequencing in aNSCLC patients treated with programmed death-1 (PD-1) blockers. Clinical data, tumor programmed death ligand-1 (PD-L1) expression, and KRAS mutational status were collected...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097095/patients-with-smarca4-deficient-thoracic-sarcoma-and-severe-skeletal-related-events
#19
Kei Kunimasa, Harumi Nakamura, Kazuko Sakai, Motohiro Tamiya, Madoka Kimura, Takako Inoue, Kazumi Nishino, Hanako Kuhara, Shin-Ichi Nakatsuka, Kazuto Nishio, Fumio Imamura, Toru Kumagai
OBJECTIVES: SMARCA4-deficient thoracic sarcoma(DTS) is a recently identified new entity of thoracic malignancies characterized by inactivation of SMARCA4. Patients with SMARCA4-DTS have a particulary aggresive clinical course and no effective treatments. However, the detailed clinical features of SMARCA4-DTS remain unclear. Here, we report the clinical courses and molecular profiles of two cases of SMARCA4-DTS. MATERIALS AND METHODS: We experienced strikingly similar two patients of SMARCA4-DTS...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097094/re-administration-of-osimertinib-in-osimertinib-acquired-resistant-non-small-cell-lung-cancer
#20
Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Toshio Kubo, Kadoaki Ohashi, Kammei Rai, Hisaaki Tanaka, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
BACKGROUND: Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). However, there is no established strategy for treatment following acquired resistance to this agent. One potential strategy for treating acquired resistance to EGFR TKIs is re-administration, which has been evaluated mainly using first- or second-generation EGFR TKIs. However, no clinical data are available with which to determine the significance of re-administration of osimertinib, a third-generation EGFR TKI...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"